Considering the role played by ibrutinib in the management of different non-Hodgkin Lymphomas (i.e., MZL, MCL, DLBCL, WM), HSP70/HSF1 axis inhibition would be of clinical relevance not only in CLL, but also in other B-lymphoproliferative diseases. Here, HSF1 is linked to marginal zone lymphoma.